NICE (UK) publishes draft guidance recommending Sof/Vel for use within NHS
Cinnamon Girl said
Sep 28, 2016
Loopy Lisa wrote:
That is fantastic news, especially for Geno 3's. That sounds a reasonable price as well. :D
Hi Lisa,
Yes indeed, very good news! Let`s hope Gen 2`s will be included as well when it eventually becomes available...
Loopy Lisa said
Sep 28, 2016
That is fantastic news, especially for Geno 3's. That sounds a reasonable price as well. :D
Cinnamon Girl said
Sep 26, 2016
NICE has published new draft guidance which recommends sofosbuvir-velpatasvir. The NICE appraisal committee concluded that sofosbuvir-velpatasvir was clinically and cost-effective, and should be routinely available on the NHS.
Sofosbuvir-velpatasvir - a tablet taken once daily - works by blocking the virus from multiplying and infecting new cells. Trials of the drug showed cure rates of 89% and above for all genotypes.
The draft guidance recommends that decisions to treat patients with sofosbuvir-velpatasvir are made by multidisciplinary teams in the operational delivery networks put in place by NHS England, and to prioritise treatment for people with the highest unmet clinical need.
Hi Lisa,
Yes indeed, very good news! Let`s hope Gen 2`s will be included as well when it eventually becomes available...
That is fantastic news, especially for Geno 3's. That sounds a reasonable price as well. :D
NICE has published new draft guidance which recommends sofosbuvir-velpatasvir. The NICE appraisal committee concluded that sofosbuvir-velpatasvir was clinically and cost-effective, and should be routinely available on the NHS.
Sofosbuvir-velpatasvir - a tablet taken once daily - works by blocking the virus from multiplying and infecting new cells. Trials of the drug showed cure rates of 89% and above for all genotypes.
The draft guidance recommends that decisions to treat patients with sofosbuvir-velpatasvir are made by multidisciplinary teams in the operational delivery networks put in place by NHS England, and to prioritise treatment for people with the highest unmet clinical need.
Full article... NICE recommends Sof/Vel
(And also see This thread for lots more information on Sof/Vel)